Table 2: Univariate and multivariate analyses of relationship between various clinical factors and overall survival (OS).

VariableCategoryObsUnivariate analysis; OSMultivariate analysis; OS
HRP95%CIHRP95%CI

GenderM/F48/380.7470.1940.481-1.160
Age<64/≥6440/461.7090.0171.102-2.6521.4780.0970.932-2.344
PLT, 109/L<258.67/≥258.6764/220.6520.0900.397-1.069
PDW, fL<17.99/>=17.9964/220.9160.7260.560-1.497
MPV, fL<12.46/>=12.4664/221.240.3880.761- 2.021
LYM, 109/L<1.5/>=1.564/220.6360.0750.387-1.046
NEU, 109/L<7.12/>=7.1264/221.1600.5530.711-1.891
PLR<240.18/>=240.1866/200.9400.8140.560-1.577
NLR<6.17/>=6.1765/211.8200.0201.098-3.0181.4570.1780.843-2.517
APTT, s<30.8/≥30.864/220.8680.5770.529-1.426
PT, s<12.3/≥12.364/221.6700.0411.020-2.7331.8290.0361.042-3.212
INR<1.07/≥1.0764/221.6700.0411.020-2.733
FIB, g/l<4.49/≥4.4964/221.3930.1960.843-2.304
TT, s<18.75/≥18.7565/210.8530.5280.519-1.399
DD, ug/ml<1.11/≥1.1163/211.2630.3410.781-2.043
ALB, g/L<35/≥3538/480.6180.0320.397-0.9601.2380.4590.704-2.176
CRP, mg/L<10/≥1025/611.3040.2720.812-2.092
GPS0/1-219/671.1980.4940.714-2.011
CA199, U/ml<37/>=3728/581.2950.2690.818-2.050
CA125, U/ml<36.49/≥36.4959/270.9700.8960.611-1.537
CEA, ng/ml<5.1/≥5.157/291.240.3500.79-1.96
DifferentiationMiddle-High/Low57/293.3820.0012.033-5.6283.0460.001 1.667-5.566
Lymph(+)/(-)39/470.7120.1270.459-1.102
Nerve(+)/(-)60/260.7560.2400.475-1.205
StageI-II/III-IVA62/241.8400.0151.126-3.0081.6210.0620.975-2.695

Obs, observation, PLT, platelet count, PDW, platelet distribution width, MPV, mean platelet volume, LYM, lymphocyte count NEU, neutrophil count, PLR, platelet-lymphocyte ratio, NLR, neutrophil-lymphocyte ratio, ALB, albumin, CRP, C-reactive protein, GPS, Glasgow Prognostic Score, APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio, FIB, fibrinogen, TT, thrombin time, DD: D-dimer, Lymph: lymph node metastasis, and Nerve, nerve invasion. OS, overall survival and RFS, recurrence-free survival.